Loading stock data…
PTHS
$26.01-1.23 (-4.52%)
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pelthos Therapeutics Inc. in the Healthcare sector is trading at $26.01. Wall Street consensus targets $57.14 (7 analysts), implying a +119.7% move over the next 12 months. The stock is currently 52% below its 52-week high of $54.29, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +119.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$26.01
Potential Downside
0%
Whystock Fair Value$26.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$57.14+119.7%
Range$48.00 – $75.00
Fundamentals
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 y...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$77.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-111.41%
Volume
Today's trading volume
44,152
Recent News
Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview
Pelthos Therapeutics (NYSEAMERICAN:PTHS) executives detailed the company’s path to the public markets, early commercial traction for its lead product ZELSUVMI, and plans to add two additional pediatric-focused dermatology products during an investor interview hosted by Roth Capital Partners senior b
Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...
Pelthos Therapeutics Inc (PTHS) reports a 129% increase in prescriptions and strategic acquisitions, bolstering its financial position and setting the stage for future growth.
Pelthos Therapeutics Q4 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported fourth-quarter and full-year 2025 results on its earnings call, highlighting rapid early demand for its lead product ZELSUVMI, two newly acquired FDA-approved dermatology products, and financing transactions that management said strengthened the bala
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.9% and